Rani Therapeutics Expands its Collaboration with Celltrion to Develop Oral Version of Humira Biosimilar RT-105
- The recent collaboration was based on the Celltrion's previous agreement with Rani in early Jan 2023 to develop an RT-111, an orally administered ustekinumab biosimilar
- Celltrion will exclusively supply Rani with an oral adalimumab formulation (CT-P17) required for RT-105 & will have a right of first refusal to negotiate a global license to RT-105, based on P-I trial
- Rani will conduct clinical trials on its proprietary technology for high-dose drug delivery & develop high-concentration oral adalimumab. The company complete the development of CT-P17 & received marketing authorization as 1st high-concentration formulation from the EMA which was recently approved in the US
Ref: Globenewswire | Image: Rani Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.